HealthQuill Immunogenicity
Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,” after a single jab, according to a company statement. 
Drugs Health Pharma

‘Strong neutralizing responses’ shown in RSV vaccine trials: Pfizer says

Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,”.

Read More
Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to 59 years has met its primary goals in trials.
Drugs Health Pharma

Last-stage trials achieve “positive” results for RSV drug: Pfizer says

HQ Team April 9, 2024: Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to.

Read More